2022
DOI: 10.3390/ijms23147728
|View full text |Cite
|
Sign up to set email alerts
|

Cardiac Troponin Biosensor Designs: Current Developments and Remaining Challenges

Abstract: Acute myocardial infarction (AMI) is considered as one of the main causes of death, threating human lives for decades. Currently, its diagnosis relies on electrocardiography (ECG), which has been proven to be insufficient. In this context, the efficient detection of cardiac biomarkers was proposed to overcome the limitations of ECG. In particular, the measurement of troponins, specifically cardiac troponin I (cTnI) and cardiac troponin T (cTnT), has proven to be superior in terms of sensitivity and specificity… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
8
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 22 publications
(9 citation statements)
references
References 92 publications
0
8
0
Order By: Relevance
“…A striking advantage of the sensor presented here is its simple and inexpensive design compared to other more complex and complicated optical methods, such as SPR [ 21 ], fluorescence, or electrochemiluminescence [ 17 , 18 ]. Other advantages of the setup are the small size and the inherent multiplexing ability to expand the approach to a set of biomarkers of interest.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…A striking advantage of the sensor presented here is its simple and inexpensive design compared to other more complex and complicated optical methods, such as SPR [ 21 ], fluorescence, or electrochemiluminescence [ 17 , 18 ]. Other advantages of the setup are the small size and the inherent multiplexing ability to expand the approach to a set of biomarkers of interest.…”
Section: Discussionmentioning
confidence: 99%
“…Therefore, it is not possible to discuss them in detail here. We refer instead to some excellent reviews covering this topic [ 17 , 18 ]. A common technique for quantifying troponin is the sandwich ELISA, which is well-established but usually a laboratory-based approach due to its heterogeneous assay principle.…”
Section: Introductionmentioning
confidence: 99%
“…Cardiac troponin T (cTnT) and troponin I (cTnI) are cardiac regulatory proteins that control the calcium-mediated interaction between actin and myosin. Indeed, troponins, our current “gold standard” biomarker criterion for the diagnosis of myocardial infarction, have high sensitivity and specificity for this diagnosis, and therapies instituted in patients with elevated troponin have been shown to influence outcomes. Previous, less sensitive methods of measuring cTn were unlikely to detect cTn, except in patients with an acute cardiac disorder. Thus, a “positive” cTn result (i.e., above the LOD) was particular.…”
Section: Introductionmentioning
confidence: 99%
“…Among the known biochemical markers of early AMI, cardiac troponin I (cTnI) is considered the golden standard in medical diagnosis [ 3 ]. In addition to being a protein specifically related to myocardial damage, it can also remain in the myocardial tissue for a long time and is released from the cells in levels of a very low concentration within 3–4 h after the onset of AMI symptoms [ 4 , 5 ]. For these reasons, a sensitive method for detecting cTnI is reasonable.…”
Section: Introductionmentioning
confidence: 99%